Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Income from Continuing Operations (2023 - 2026)

ArriVent BioPharma has reported Income from Continuing Operations over the past 4 years, most recently at 43320000.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 43320000.0 for Q1 2026, up 32.72% from a year ago — trailing twelve months through Mar 2026 was 145241000.0 (down 13.95% YoY), and the annual figure for FY2025 was 166308000.0, down 106.62%.
  • Income from Continuing Operations reached 43320000.0 in Q1 2026 per AVBP's latest filing, down from 35544000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 12172000.0 in Q1 2023 and bottomed at 64387000.0 in Q1 2025.
  • Median Income from Continuing Operations over the past 4 years was 21567000.0 (2023), compared with a mean of 27649923.08.
  • The largest annual shift saw Income from Continuing Operations crashed 269.68% in 2025 before it soared 32.72% in 2026.
  • Over 4 years, Income from Continuing Operations stood at 21193000.0 in 2023, then rose by 2.64% to 20633000.0 in 2024, then tumbled by 72.27% to 35544000.0 in 2025, then decreased by 21.88% to 43320000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for AVBP at 43320000.0 in Q1 2026, 35544000.0 in Q4 2025, and 34978000.0 in Q3 2025.